Actinic keratosis (AK) is an area of dysplastic epidermal keratinocytes that undergo transformation due to substantial ultraviolet (UV) exposure [
1], and the distribution of these lesions reflects areas of the body that are most sun-exposed, namely the face, scalp and arms. Within these regions, numerous lesions are often found and premalignant cells are thought to exist within the normal skin alongside AK, so called ‘field cancerization’ [
2]. The rate of transformation to squamous cell carcinoma (SCC) is low [
3], however, the overall risk of skin cancer is increased in the presence of AK, therefore, warranting their detection and treatment. Current treatment modalities available for AK comprise lesion-directed therapies such as cryotherapy and surgical excision, and the field-directed therapies, namely the topical agents 5-fluorouracil, diclofenac and imiquimod [
4]. The advantage of field therapies is that they target both clinically apparent and subclinical lesions over a contiguous area of application [
5]. Developed in Australia, ingenol mebutate (Picato
®, LEO Pharma A/S, Ballerup, Denmark) is a promising new topical chemotherapeutic that is quickly gaining acceptance as an effective field therapy against AK [
6]. Ingenol mebutate was approved for use in Australia in 2013. It is derived from the sap of the Euphorbia peplus plant, which has already been in widespread use as a traditional herbal remedy for various dermatological lesions [
7]: Ingenol mebutate has been trialed for other skin lesions such as superficial basal cell carcinoma [
8]. A key reason behind the increasing relevance of ingenol mebutate as a treatment for AK is that it is efficacious in the destruction of AK lesions after a period of as little as 2–3 days [
9], compared with the current topical agents that are applied for weeks to months [
10]. This shorter duration of application translates to a number of obvious clinical benefits; a shorter duration of adverse effects, should they occur, as well as improved patient adherence comparative to alternative treatments. Given the relative infancy of ingenol mebutate as a dermatologic therapy, this brief review aims to summarize the key points of this agent.